CytoArm, founded in 2020, focus on untreatable diseases through next generation T cell therapy, Armed-T cell. We are led by experts in both business & medical area, with comprehansive experience to develop novel T cell therapy in clinical treatment
Company Details
- Employees
- 9
- Founded
- -
- Address
- 台北市, 台北市 105, Tw
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.cytoarm.com/
- Keywords
- cancer treatment, Autologous Cell Therapy, Armed-T cell, bispecific antibody, Immunotherapy, T-Cells, cell therapy.
- HQ
- 台北市, 台北市
Cytoarm｜bsab Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment Questions
Cytoarm｜Bsab Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment's website is https://www.cytoarm.com/
Cytoarm｜Bsab Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment's LinkedIn profile is https://tw.linkedin.com/company/cytoarm
Cytoarm｜Bsab Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment has
9 employees.
View email and phone details for 9
employees at Cytoarm｜Bsab Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment.
Cytoarm｜Bsab Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment's industry is
Biotechnology Research
Cytoarm｜Bsab Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment's top competitors are
Sylvarum,
Immutrain - Training Network For The Immunotherapy Of Cancer,
Network For Optimizing Adoptive T Cell Therapy (T-Op),
Precisemab Biotech Co., Ltd.,
Singapore Flying College,
Novascope,
Takeda,
Bloodscan Biotech Inc.,
Eirgenix, Inc.,
Acrocyte Therapeutics.
Cytoarm｜Bsab Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment's categories are Biotechnology Research
Cytoarm｜Bsab Armed-T Therapy Platform Revolutionizing T Cell Cancer Treatment's founding year is 2020
